drugset / Trial / NCT03496662
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1/2
Completed
40 enrolled
Washington University School of Medicine
Bristol-Myers Squibb · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collabThe Foundation for Barnes-Jewish Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel. The investigators will be looking at both the side effects and the way the disease responds to treatment.
Timeline
- Start
- 2018-08-31
- Primary completion
- 2021-10-28
- Completion
- 2024-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-813160 | Small molecule | 300 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |